A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia

Chronic lymphocytic leukaemia (CLL) affects white blood cells, which are an essential part of the body's immune system. Over time, abnormal cells build up in the blood, bone marrow, and lymph nodes. For many years, standard treatment in the UK has relied on combinations of chemotherapy tablets and antibody drips given into a vein. While these treatments can work well, researchers want to see if newer, targeted medications can provide better long-term control with fewer side effects.

This Phase 3 trial focuses on a targeted medicine called acalabrutinib (brand name Calquence). Instead of attacking all fast-growing cells like traditional chemotherapy does, acalabrutinib works by blocking a specific protein inside leukaemia cells that helps them survive and multiply. In this study, doctors are comparing acalabrutinib—either taken by itself or combined with an antibody therapy called obinutuzumab—against the standard combination of obinutuzumab and chlorambucil chemotherapy.

Doctors want to measure progression-free survival, which means how long people live without their leukaemia getting worse. They will also look at overall survival and carefully record how well patients tolerate each treatment. Because this is a Phase 3 study, these medicines have already shown promise in earlier trials; this final stage helps confirm whether targeted treatments should become the preferred first-line choice for people living with CLL.